Skip to main content

Table 2 Association of MAFLD and MAFLD subtypes with systemic atherosclerosis

From: Association of metabolic dysfunction-associated fatty liver disease with systemic atherosclerosis: a community-based cross-sectional study

Factor

N

Extent of atherosclerotic plaquesa

Extent of atherosclerotic stenosisa

PolyVDb

Adj. cOR (95% CI)

P value

Adj. cOR (95% CI)

P value

Adj. OR (95% CI)

P value

Non-MAFLD

1578

Ref.

 

Ref.

 

Ref.

 

MAFLD

1469

2.14 (1.85–2.48)

 < 0.001

1.47 (1.26–1.71)

 < 0.001

1.55 (1.24–1.94)

 < 0.001

DM-MAFLD

426

2.84 (2.25–3.57)

 < 0.001

2.00 (1.61–2.47)

 < 0.001

1.92 (1.42–2.60)

 < 0.001

OW-MAFLD

912

1.97 (1.67–2.33)

 < 0.001

1.29 (1.08–1.53)

0.004

1.39 (1.07–1.80)

0.01

Lean-MAFLD

131

1.63 (1.14–2.34)

0.007

1.18 (0.81–1.72)

0.38

1.36 (0.79–2.36)

0.27

  1. MAFLD, metabolic dysfunction-associated fatty liver disease; PolyVD, polyvascular disease; DM, diabetes mellitus; OW, overweight or obesity; Adj., adjusted; cOR, common odds ratio; OR, odds ratio; CI, confidence intervals; Ref., reference
  2. All models were adjusted for sex, age, marital status, education, income, current smoking, current drinking, sleep time, sedentary time, family history of ASCVD, eGFR, lipid-lowering medication, antiplatelet medication, and anticoagulants medication
  3. aThe extent of atherosclerotic plaques and stenosis was defined according to the number of 8 vascular sites affected and was divided into four groups, including 0, 1, 2–3, and 4–8 vascular sites. Adjusted cOR and 95% CI were calculated by the ordinary logistic regression model
  4. bPolyVD was defined as the presence of atherosclerotic stenosis in at least two vascular sites. Adjusted OR and 95% CI were calculated by the binary logistic regression model
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840